Biological Aging of Skeletal Muscles in Humans

HEALTHY Clinical Trial

— BioAge  

Official title:

Biological Aging of Skeletal Muscles in Humans, a Monocentric, Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02675192
• Other study ID #: 1508145
• Secondary ID: 2015-A01484-45
• Status: Completed
• Start date: February 18, 2016
• Est. completion date: May 23, 2017

Study information

• Verified date: May 2021
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aging affects almost all the tissues and physiological functions, and skeletal muscle is the most affected organ. The progressive decline of the weight and the muscular function linked to the aging contributes to the lack of autonomy and dependence, but also to an increase of the mortality risks. Sarcopenia is also a prevalent condition, because it is detected in 13-24% of 60 years old, and 50% of 80 years old and more.

However, strong inter-individual variations of this prevalence of sarcopenia exists. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.

In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.

Description:

Aging affects almost all the tissues and physiological functions, and skeletal muscle is the most affected organ. The progressive decline of the weight and the muscular function linked to the aging contributes to the lack of autonomy and dependence, but also to an increase of the mortality risks. Sarcopenia is also a prevalent condition, because it is detected in 13-24% of 60 years old, and 50% of 80 years old and more.

However, strong inter-individual variations of this prevalence of sarcopenia exists. Some elderly (60 years old) reveal a biological aging of 80 years old, whereas 60 years old people reveal a biological aging of 60 years old. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.

Previous sarcopenia studies in Humans did not really focus on chronological aging, they were all based on a comparison between young and old people. No study considered inter-individual modifications (biological aging) in sarcopenia. Furthermore, few studies were associated in the same study to "omic", histological, and epigenetic data, to obtain integrated point of view of Human Sarcopenia.

In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: May 23, 2017
• Est. primary completion date: January 20, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 80 Years to 83 Years

Eligibility

Inclusion Criteria:

• Belonging to the Proof cohort

• Between 80 and 83 years old

• Informed consent signed

• Genetic analyses consent signed

• Subject affiliated or entitled to a social security scheme

Exclusion Criteria:

• Anti coagulative treatment

• Severe obesity (>35)

• All chronic pathology requiring a treatment

• Severe renal insufficiency (discovery less than 6 months)

• Abnormal coagulation appraisal

• Allergy to local anesthetics

• Installation of a prosthetic hip and / or knee in the last six months

• Senile dementia

• Refusal of genetic study

Related Conditions & MeSH terms

• HEALTHY

Intervention

Other:
• Proof cohort : muscular assessment
Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.

Locations

Country	Name	City	State
France	Chu Saint Etienne	Saint Etienne

Sponsors (4)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Ecole Nationale Superieure Lyon, Institut National de la Recherche Agronomique, Region Rhone Alpes

Country where clinical trial is conducted

France, 

References & Publications (1)

Barthélémy JC, Pichot V, Dauphinot V, Celle S, Laurent B, Garcin A, Maudoux D, Kerleroux J, Lacour JR, Kossovsky M, Gaspoz JM, Roche F. Autonomic nervous system activity and decline as prognostic indicators of cardiovascular and cerebrovascular events: the 'PROOF' Study. Study design and population sample. Associations with sleep-related breathing disorders: the 'SYNAPSE' Study. Neuroepidemiology. 2007;29(1-2):18-28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area of type IIA fibers called vastus lateralis.	The primary endpoint is the cross sectional area (measured in µm2) of type IIA fibers from the vastus lateralis muscle biopsies.	Day 15